Viridian Therapeutics Inc
VRDN
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,561.80 | 49.90 | -0.58% |
| CAC 40 | 7,910.49 | 31.93 | -0.40% |
| DAX 40 | 24,122.40 | 86.29 | 0.36% |
| Dow JONES (US) | 41,860.44 | 816.80 | -1.91% |
| FTSE 100 | 8,786.46 | 5.34 | 0.06% |
| HKSE | 23,695.88 | 131.90 | -0.55% |
| NASDAQ | 18,872.64 | 270.07 | -1.41% |
| Nikkei 225 | 36,914.18 | 384.80 | -1.03% |
| NZX 50 Index | 12,650.24 | 52.86 | -0.42% |
| S&P 500 | 5,844.61 | 95.85 | -1.61% |
| S&P/ASX 200 | 8,340.90 | 45.90 | -0.55% |
| SSE Composite Index | 3,387.63 | 0.05 | 0.00% |